Research study Program year 2025 Source: CMS Open Payments

A Two-Part Phase 1 Randomized, Double-Blind, Placebo-Controlled Study

Research payments

$349,270

29 payments

Through program year 2025, $349,270 in research payments was reported against A Two-Part Phase 1 Randomized, Double-Blind, Placebo-Controlled Study, across 29 payments, paid by GlaxoSmithKline, LLC..

Paid by: GlaxoSmithKline, LLC.
ClinicalTrials.gov: No trial number was reported for this study

By program year

1 row

Year	Kind	Amount	Payments
2025	Research	$349,270	29

Breakdown

Who paid Research payments · program year 2025

GlaxoSmithKline, LLC. $349,270 29 payments

Who received the money Research payments · program year 2025

Harmony Medical Research Institute Organisation paid for research $97,971 4 payments
Ppd Development INC Clinics Organisation paid for research $85,017 1 payment
Clincept LLC Organisation paid for research $51,610 6 payments
Yuma Pulmonary Associates Organisation paid for research $37,049 6 payments
Clinical Research Of Rock Hill Organisation paid for research $27,793 6 payments
Hull And Hull Medical Specialists LLP Organisation paid for research $20,073 2 payments
Carolina Research Center Organisation paid for research $19,477 3 payments
Velocity Clinical Research INC Organisation paid for research $10,279 1 payment

Usually the institution or organisation running the study, not a person.

Records

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

Principal investigators named

8 shown

Named on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.

What you are looking at

Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.